FDA
Rejected Twice: Replimune's RP1 and the 22 Scientists Who Disagreed
FDA rejected Replimune's RP1 for advanced melanoma for the second time on April 10, citing the same reason it cited last July: heterogeneity of the…
Latest — Page 18
Deals
Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…
Deals
Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory
Daiichi Sankyo will sell its consumer health subsidiary to Suntory Holdings for 246.5 billion yen, about $1.55 billion, paid in tranches over three years.
Deals
Filed: Nir Zuk's Bid for $442M-Asset Liberty Bank
Nir Zuk, the Israeli billionaire who founded Palo Alto Networks, filed a Federal Reserve application Wednesday to acquire voting shares of DMG Bancshares…
FDA
Recalled: Viatris Xanax Lot, Teva's 7 Clonidine Batches
FDA graded two separate recalls Class II this week: Viatris pulling extended-release Xanax over failed dissolution specs, Teva yanking clonidine patches…
Deals
OpenEvidence and Tandem Merge $13B in AI Into One Prescription Workflow
OpenEvidence and Tandem linked their platforms to automate the gap between clinical decisions and prior auth approvals.
deals
Legal
Huizenga Filed Bill to Sanction DeepSeek Under 1977 Law
If the Deterring American AI Model Theft Act passes, companies like DeepSeek, Moonshot, and MiniMax could face placement on the Commerce Department's Entity…
Legal
FTC Sues NERD Solutions for $8.8M Student Loan Scheme
The FTC sued NERD Solutions Inc., ED REF Inc., and their operators Natalie Rodriguez and Pablo Ortiz in the U.S. District Court for the Central District of…
Legal
Judge Orders Drillmec VP to Forfeit $1,019,757 in PEMEX Bribery Case
Judge David Hittner in the Southern District of Texas ordered Diego Bergonzi to forfeit $1,019,757 earlier this week, the exact proceeds Bergonzi pocketed…
Legal
Judges Dismissed 5 FCPA Cases Over DOJ Misconduct in 26 Trials
Judge Howard Matz called it "an unusual and extreme picture of a prosecution gone badly awry.
Deals
Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…
Deals
Aligos Sells China HBV Rights to Amoytop in $445M Deal
Aligos Therapeutics sold the Greater China rights to pevifoscorvir sodium to Fujian-based Amoytop for up to $445 million: $25 million upfront and $420…
Deals
Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win
Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting…
Deals
Revolution Medicines Prices Record Raise, Biotech's Biggest Since Pandemic
Revolution Medicines just priced a public equity raise, the largest single biotech offering since the Covid-19 pandemic.
SEC
FDIC, OCC Bar Reputation Risk as Debanking Basis Starting June 6
The FDIC and OCC just banned reputation risk as a basis for bank supervision.
